

SERVIZIO SANITARIO REGIONALE
EMILIA ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO ROMAGNOLO
PER LO STUDIO
DEI TUMORI
"DINO AMADORI"

THE LYMPHOMAS CONFERENCE

III EDITION

ROME
08/09
MAY
2026



A. ROMA LIFESTYLE HOTEL, ROME
Via Giorgio Zoega, 59

PRESIDENTS:

Gerardo Musuraca, Nicola Normanno

SCIENTIFIC SECRETARIAT:

Claudio Cerchione, Eliana Liardo,
Alessandro Lucchesi, Francesco Malaspina,
Giovanni Martinelli, Margherita Parolini,
Costantino Riemma, Jessica Rosa, Pietro Rossi

PROMOTED BY

Unità Ematologia e Trapianti IRCCS IRST "Dino Amadori" Meldola

ORGANIZING SECRETARIAT



REGISTRATION



- ① Download the "PROEVENTI" app on your smartphone.
- ② Login or create a new account.
- ③ Enter the event pin: **LYMPHOMAS26**.
- ④ You are now on the event page, click on "**REGISTRATION**" at the top left.

The Conference has been accredited to the Italian Ministry of Health:

Event n. 476317 Provider n. 2773

ECM Credits n. 9,1 for:

Medical Surgeon (interdisciplinary area), Pharmacist.

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles - treatment profiles.


Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

Participation at the event is free of charge, but registration is compulsory.
THE REGISTRATION DEADLINE IS 05 MAY 2026.



PROMOTED BY



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

PATRONAGE



ASSOCIAZIONE
ITALIANA
ONCOLOGIA
MEDICA



FONDAZIONE
ITALIANA
LINFOMI



SIAM

Società Italiana Intelligenza Artificiale in Medicina

FACULTY

ALINARI LAPO	OHIO STATE UNIVERSITY, COLUMBUS
CERCHIONE CLAUDIO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
COX MARIA CHRISTINA	POLICLINICO UNIVERSITARIO TOR VERGATA, ROMA
CUNEO ANTONIO	UNIVERSITÀ DEGLI STUDI DI FERRARA
DALLA FAVERA RICCARDO	COLUMBIA UNIVERSITY, NEW YORK
DERENZINI ENRICO	IEO ISTITUTO EUROPEO DI ONCOLOGIA, MILANO
FERRERI ANDRES	UNIVERSITÀ VITA-SALUTE SAN RAFFAELE MILANO
GAIDANO GIANLUCA	UNIVERSITÀ DEL PIEMONTE ORIENTALE
HOHAUS STEFAN	UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA
KUPPERS RALF	INSTITUTE OF CELL BIOLOGY, UNIVERSITY HOSPITAL ESSEN, GERMANY
LANZA FRANCESCO	OSPEDALE S. MARIA DELLE CROCI, RAVENNA
LAURENTI LUCA	POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS, ROMA
LIARDO ELIANA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
LUCCHESI ALESSANDRO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
LUMINARI STEFANO	UNIMORE, MODENA
MADDOCKS KAMI	OHIO STATE UNIVERSITY, COLUMBUS
MALASPINA FRANCESCO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
MARTELLI MAURIZIO	UNIVERSITÀ LA SAPIENZA, ROMA
MARTINELLI GIOVANNI	ISTITUTO DI EMATOLOGIA "L. E. A. SERÀGNOLI", BOLOGNA
MUNIR TALHA	LEEDS TEACHING HOSPITALS NHS TRUST, UK
MUSURACA GERARDO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
NORMANNO NICOLA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)

NOWAKOWSKI GREG	MAYO CLINIC COMPREHENSIVE CANCER CENTER, ROCHESTER
PAROLINI MARGHERITA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
PASQUALUCCHI LAURA	COLUMBIA UNIVERSITY, NEW YORK
PIAZZA FRANCESCO	UNIVERSITÀ DEGLI STUDI DI PADOVA
PIERINI ANTONIO	AZIENDA OSPEDALIERA DI PERUGIA
PILERI ALESSANDRO	POLICLINICO S. ORSOLA, BOLOGNA
PINTO ANTONELLO	IRCCS ISTITUTO NAZIONALE TUMORI FONDAZIONE G. PASCALE, NAPOLI
PULSONI ALESSANDRO	UNIVERSITÀ SAPIENZA, ROMA
RIEMMA COSTANTINO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
ROSA JESSICA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
ROSCHEWSKI MARK	MEMORIAL SLOAN-KETTERING CANCER CENTER, NEW YORK
ROSSI DAVIDE	EOC SVIZZERA, BELLINZONA
ROSSI PIETRO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
SCARFO' LYDIA	OSPEDALE SAN RAFFAELE, MILANO
SCHUSTER STEPHEN	ABRAMSON CANCER CENTER UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA
SILKENSTEDT ELISABETH	ROBERT-BOSCH-HOSPITAL, STUTTGART
STAUDT LUIS	NATIONAL CANCER INSTITUTE, WASHINGTON
SUREDA ANNA	HOSPITALUNIVERSITARI DEXEUS, BARCELONA
TOSI PATRIZIA	OSPEDALE DI RIMINI
TREON STEVEN	BING CENTER FOR WALDENSTROM'S MACROGLOBULINEMIA DFCI, BOSTON
VITOLO UMBERTO	IRCCS CANDIOLLO (TO)
ZUCCA EMANUELE	EOC SVIZZERA, BELLINZONA

GENERAL INFORMATION

WELCOME TO ROME & GENERAL INFO

LANGUAGE

The official language of the Congress is English. All presentations and scientific materials will be provided in English.

CLIMATE

The local climate in Rome during the event period is typically temperate. The average temperature ranges between 16°C and 27°C.

CURRENCY & BANKING

The official currency is the Euro (€). Foreign currencies can be exchanged at banks, which are generally open Monday to Friday, from 08:30 to 13:30. Most shops and restaurants accept major credit cards.

TAXI SERVICE

To call a taxi, the single number is 060609.

- From Fiumicino Airport: €48.
- From Ciampino Airport: €30.
- From Termini to city centre: between €8 and €15.

KEY INFORMATION

VENUE & GETTING AROUND

VENUE

A. ROMA LYFESTYLE HOTEL
Via Giorgio Zoega, 59, 00164 -
Roma, Italy.



WIFI available in every area.

HOTEL INFORMATION

For hotel information and reservation please visit the Hotel & Groups Desk.



Termini railway station in 10km from the hotel.



A. Rome Lyfestyle Hotel is connected to Rome's centre via Tram Line no. 8.

The nearest stop is within walking distance, providing direct access to Piazza Venezia in 15-20 minutes.



A complimentary shuttle to and from the city centre is available for guests from 08:30 to 21:00. Note that this service is limited. Reservation is mandatory.

SCIENTIFIC RATIONALE

Lymphoid malignancies represent one of the most biologically heterogeneous and therapeutically dynamic areas in modern hematology.

Over the last decade, major advances in genomics, tumor microenvironment characterization, immune biology, and translational research have profoundly reshaped the classification, prognosis, and treatment of lymphomas. At the same time, the rapid expansion of novel therapeutic strategies—including targeted agents, antibody–drug conjugates, bispecific antibodies, and cellular therapies—has introduced unprecedented opportunities, but also significant clinical and strategic challenges.

The Lymphomas Conference – 3rd Edition is conceived as an international, high-level scientific forum aimed at integrating

biological insights with clinical decision-making, fostering a comprehensive and forward-looking discussion on both common and rare lymphoid malignancies.

The meeting brings together leading basic scientists, translational researchers, and clinicians to critically analyze how molecular biology, genetics, epigenetics, immune interactions, and artificial intelligence are redefining disease understanding and therapeutic paradigms.

A central focus of the conference is Diffuse Large B-Cell Lymphoma (DLBCL), used as a model to illustrate the transition from biologically driven classification to precision treatment strategies, including optimal sequencing of immunochemotherapy, bispecific antibodies, CAR T-cell therapies, and emerging cellular platforms.


Similar integrative approaches are extended to Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia, and special lymphoma entities, addressing both frontline and relapsed/refractory settings.


Special attention is devoted to unmet clinical needs, such as the management of elderly and frail patients, high-grade and transformed lymphomas, resistance mechanisms, minimal residual disease monitoring through circulating tumor DNA, and the evolving role of allogeneic transplantation in the era of immune and cellular therapies.

Through interactive sessions, expert panels, and multidisciplinary discussions, the conference aims to:

- Bridge the gap between biological discovery and clinical practice
- Promote critical evaluation of emerging therapies and treatment algorithms
- Encourage rational sequencing and personalization of care
- Stimulate collaboration among international experts across disciplines.

Ultimately, The Lymphomas Conference – 3rd Edition seeks to provide participants with a clear, evidence-based, and future-oriented framework to improve outcomes and quality of care for patients with lymphoid malignancies in an increasingly complex therapeutic landscape.





08.05.2026

DAY 1

8:30 REGISTRATION

WELCOME AND INTRODUCTION

→ SESSION 1:

The biology of the Diffuse Large B cell Lymphoma

Chairs: Gerardo Musuraca and Giovanni Martinelli

09:00 – 09:20

• *Louis Staudt*

The pathways of Diffuse large B-cell lymphomas (DLBCL):
Classifications and artificial intelligence to understand the “enemy”

09:20 – 09:40

• *Riccardo dalla Favera*

What we know about the genetics of diffuse large cell lymphoma
and how it makes it work

09:40 – 10:00

• *Laura Pasqualucci*

Microenvironment and interaction with genetics in controlling
DLBCL development and resistance

10:00 – 10:10

• *L. Staudt, L. Pasqualucci, R. Dalla Favera, G. Martinelli, G. Musuraca*

“Rumble in the jungle”

Which are the best drivers? Suggestions for future therapies

→ SESSION 2:

Diffuse Large B cell Lymphoma: Treatment strategies - PART A

Chairs: Umberto Vitolo, Greg Nowakoski, Claudio Cerchione

10:10 - 10:30

• *Grzegorz Nowakowski*

Biology driven or agnostic: The Multiverse in the first line of DLBCL

10:30 - 10:50

• *Stephen Schuster*

Relapsed/refractory: The CAR T way and the current landscape of cellular therapies

10:50 - 11:20

• *Gerardo Musuraca*

Relapsed/refractory: Looking for the best sequencing or salvage strategy (Bispecifics, Drug conjugates and friends)

11:20 - 11:40

• *Lapo Alinari*

Relapsed/refractory LBCL: The evolution of the CAR T cells: Allo, NK, bi or trispecific

11:40 - 11:50 COFFEE BREAK

→ **SESSION 2:**

Diffuse Large B cell Lymphoma: Treatment strategies - PART B

Chairs: Stefan Hohaus, Patrizia Tosi, Mark Roschewsky

11:50-12:10

- *Grzegorz Nowakowski*
High Grade Lymphomas

12:10-12:30

- *Umberto Vitolo*
Next strategies and molecules on the window

12:30-12:50

- *Mark Roschewsky*
ctDNA in Large B cell Lymphoma

12:50-13:10

- *Francesco Malaspina*
Artificial intelligence in the DLBCL "Instructions for use " to build future treatments of DLBCL

**13:10 - 14:10 LUNCH SYMPOSIUM
ROOM: GIOVE 2**

Sponsored Symposium NO ECM - with the contribution of ABBVIE

Chair: Gerardo Musuraca

13:10-13:30

- *Francesco Piazza*
Learning from italian experience: from the speed of action to the management of patients with epcoritamab in R/R NHL

13:30-13:35

Discussion

→ **SESSION 3:**

Hodgkin Lymphoma

Chairs: Antonello Pinto, Anna Sureda

14:10-14:30

• *Ralf Kuppers*

The biology of Hodgkin Lymphoma

14:30-14:50

• *Antonello Pinto*

First-line treatment in Hodgkin lymphoma: The evolving landscape

14:50-15:20

• *Anna Sureda*

Relapsed/refractory HL: Salvage treatments strategies: All you need to know about transplant and new drugs

15:20-15:30

• *A. Sureda, A. Pinto, R. Kuppers*

"Rumble in the jungle"

The wind of change in Hodgkin Lymphoma

15:30 - 15:50 COFFEE BREAK

→ **SESSION 4:**

Mantle cell lymphoma

Chairs: Enrico Derenzini, Kami Maddocks

15:50-16:20

• *Kami Maddocks*

Lecture: From the biology to target cure. A risk based approach in the Front line strategies

16:20-16:40

• *Elisabeth Silkenstedt*

Salvage treatments in relapsed or refractory patients: Now and beyond.

16:40-17:00

• *Lapo Alinari*

CAR T cells in MCL: Current landscape and future prospectives.

17:00-17:10

• *K. Maddocks, E.Silkenstedt, L. Alinari, E. Derenzini*

"Rumble in the jungle"

What we have ahead in mantle cell lymphoma

→ **SESSION 5:**

Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia

Chairs: Emanuele Zucca , Davide Rossi

17:10-17:30

• *Davide Rossi*

Marginal zone Lymphoma: A particular journey from the biology to the clinic in first line.

17:30-17:50

• *Emanuele Zucca*

Marginal zone lymphoma: From the failure of the front line to the next future

17:50-18:20

• *Steven Treon*

Waldenstrom Macroglobulinemia: From diagnosis to therapy: What we have learned and what lies ahead


Chair: Francesco Lanza

18:20-18:50

• *Antonio Pierini*

Lecture: Allotransplant in Lymphoma: Who, when and How ? Update in 2025 in the era of cell therapies and new drug

18:50 CLOSING DAY REMARKS



09.05.2026

DAY 2

→ SESSION 6:

Follicular lymphoma

Chairs: Alessandro Pulsoni, Alessandro Lucchesi

08:50-09:10

- *Laura Pasqualucci*

Genetic and Epigenetic of transformation in Follicular lymphoma

09:10-09:30

- *Stefano Luminari*

First line therapy: State of the art and state of the future

09:30-09:50

- *Pietro Rossi*

Relapse/refractory disease before and beyond CAR T

09:50- 10:10

- *Stephen Schuster*

CAR T cell: Is there a role in follicular lymphoma instead of other compounds?

10:10 – 11:05 COFFEE BREAK SYMPOSIA
ROOM: GIOVE 2

Chairs: Gerardo Musuraca

Sponsored Symposium NO ECM - with the contribution of ABBVIE

Sailing through the Bcl-2 inhibition pathway

10:10-10:30

- *Gianluca Gaidano*

V+X: venetoclax as the backbone therapy in 1L and R/R CLL

10:30-10:35

Discussion

Sponsored Symposium NO ECM - with the contribution of LILLY

Translating Novel BTK Inhibition into Clinical Decisions

10:35-10:50

- *Antonio Cuneo*

Treatment Guidelines and Clinical Efficacy of Pirtobrutinib: Evidence from the BRUIN-CLL-321

10:50-11:00

- *Enrico Derenzini*

Clinical Practice: A Case-Based Discussion in Relapsed/Refractory CLL

11:00-11:05

Discussion

→ SESSION 7:

Chronic Lymphocytic Leukemia

Chairs: Luca Laurenti

11:05-11:25

• *Gianluca Gaidano*

The biology that leads to treatment: Why the drugs work in CLL

11:25-11:45

• *Lydia Scarfo'*

The right treatment in the right patient: Which first-line and why ?

11:45-12:05

• *Talha Munir*

What we have to use and when, if we fail in CLL

→ **SESSION 8:**

Special types of lymphomas

Chairs: Maurizio Martelli, Christina Cox

12:05-12:25

• *Enrico Derenzini*

T-cell lymphomas: From the biology to the treatments

12:25-12:50

• *Andres Ferreri*

Primary CNS Lymphoma: Everything you need to know

12:50-13:10

• *Maurizio Martelli*

Primary Mediastinal Diffuse large B cell lymphoma: Do we know what the best strategy is to treat it?

13:10-13:30

• *Mark Roschewsky*

Burkitt Lymphoma: To know and tame the monster

13:30-13:50

• *Alessandro Pileri*

Primary cutaneous lymphomas

13:50 CLOSING REMARKS
GERARDO MUSURACA, NICOLA NORMANNO

13:50 LUNCH BOX

SEE YOU NEXT YEAR!

GOLD

abbvie *Lilly* A MEDICINE COMPANY

SILVER

AstraZeneca  BeOne

Johnson&Johnson 

BRONZE

 GILEAD

 Kite


 Incyte

SOLVE
ON.

 KYOWA KIRIN

 sobi

 Takeda

The background features several 3D rendered structures. At the top center is a large, glowing blue spherical structure with a complex, interconnected mesh-like surface. To its right, a portion of a bright yellow, textured structure is visible. Below these, several smaller, glowing blue spherical structures of varying sizes are scattered across the dark blue background. At the bottom, a larger, glowing blue structure with a similar mesh-like surface is shown, with several thin, radiating lines extending downwards from its base. The overall aesthetic is scientific and futuristic.

FROM BIOLOGICAL INSIGHTS TO PERSONALIZED CARE: SHAPING THE FUTURE OF LYMPHOMA TREATMENT.

An international forum dedicated to integrating genomics, immune biology, and novel therapeutic strategies to improve outcomes and quality of care for patients with lymphoid malignancies.